Caribou finds a match
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Henlius goes on the anti-Pfizer offensive
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
GSK’s trio of cancer discontinuations
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
Merck gets two Welireg wins
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Triple meeting 2025 – Halda’s proximity play in prostate
Early data with the RIPTAC HLD-0915 look competitive.
